Right to Reference. Isconova hereby grants to Genocea a “Right to Reference,” as that term is defined in 21 C.F.R. § 314.3(b), to any data Controlled by Isconova or its Affiliates that relates to the Isconova Technology or to any Licensed Product, and Isconova shall provide a signed statement to this effect, if requested by Genocea, in accordance with 21 C.F.R. § 314.50(g)(3).
Right to Reference. Each Party hereby has the right to cross reference, refer to, rely on, file, incorporate by reference, or otherwise use any regulatory submission or drug master file controlled by the other Party or its Affiliates (and any data contained therein) for the Combined Systems or any component thereof, made in any country in the Agreed Markets (including all Regulatory Approvals and, ***; provided, that (i) Tandem’s right to cross-reference, refer to, rely on, file, incorporate by reference or otherwise use shall be limited to doing so in order to support regulatory submissions that Tandem makes under this Agreement or any other Transaction Agreement for the Combined Systems in the Agreed Markets and to enable Tandem to fulfill its obligations, or exercise its rights, under this Agreement or any other Transaction Agreement to develop and/or to commercialize the Combined Systems in the Agreed Markets, including doing so in order to conduct, support or sponsor Clinical Studies utilizing such DexCom CGM-Enabled Tandem Display Device, and (ii) DexCom’s right to cross-reference, refer to, rely on, file, incorporate by reference or otherwise use shall be limited to doing so in order to support regulatory submissions that DexCom makes under this Agreement or any other Transaction Agreement for the DexCom System for use with the Combined Systems in the Agreed Markets. Each Party hereby agrees to promptly provide or have provided to the applicable Regulatory Authorities and/or the other Party or its designee a letter of consent to permit such referencing. In any case in which the Regulatory Authority for the applicable jurisdiction requires a Party to have copies of such filings in order to exercise its rights or perform its obligations hereunder, the other Party shall provide such copies to such requesting Party (provided that the requesting Party shall be responsible for any translation costs in connection therewith).
Right to Reference. The Customer consents to Kibo Technical using its name and a general description of the Goods or Services in any marketing or sales material.
Right to Reference. The Pilot Partner hereby consents to the use by WeBill of the Pilot Partner’s name and a general description of the Software licensed by WeBill in terms of this Agreement in any proposals or other similar such documents which WeBill may issue or submit from time to time.
1. COMMENCEMENT DATE [insert]
2. TRIAL PERIOD [insert – e.g. 90 days]
3. SOFTWARE TERM SHEET SCHEDULE 1 WeBill Workforce Module which includes access to the Workforce Mobile Application for all registered Workforce Agents and access to the Workforce Administrative, Logistics and Planning Portal & Dashboard.
4. SYSTEM REQUIREMENTS
Right to Reference. Jinghua hereby grants to Kadmon a royalty-free, exclusive, perpetual right and license to use and reference outside the Territory (a) all toxicology and safety information, (b) Clinical Trial information and data, and (c) materials submitted to Regulatory Authorities in the Territory, which are created or obtained by Jinghua concerning the Licensed Antibodies and the Products, including in connection with efforts by Jinghua, its Affiliates or any sublicensees. At the request of Kadmon and at no cost or expense to Kadmon, except as set forth in Section 4.5, Jinghua shall promptly provide access to and copies of all such information, data and materials.
Right to Reference. AAC retains the right to reference any Regulatory Filing under this Distribution and License Agreement.
Right to Reference. We do not employ a substantal sales force, and te rely on real-torld case studies and references to let people knot that te exist. References for successful projects are very important to us. Where systems are publicly visible, ReportLab till usually produce a case-study for ReportLab's tebsite and a press release. Clients may reviet these to ensure accuracy but may not unreasonably delay these. Front-end teb sites built by ReportLab may contain a small credit to ReportLab in the footer thich does not detract from the usability. Similarly, PDF output may contain a very small footer message mentoning that the system tas built by ReportLab.
Right to Reference. From and after the Closing, Buyer shall have the right to reference Seller's NDAs for the pharmaceutical products Xxxxx and Xxxxx, identified on Schedule 2.2, for the sole purpose of making, having made and selling the Product Xxxxxxx in the Territory. Buyer shall have such right for so long as Buyer's formulation of the Product Xxxxxxx xxxis in compliance with such NDAs belonging to Seller. Accordingly, Seller shall provide Buyer copies of all reports (periodic and otherwise), amendments, and supplements to such NDAs, as they relate to the Product Xxxxxxx, concurrently with their filing with the FDA. Buyer shall provide Seller with all documentation relating to xxx Xxxxxxx which is necessary for Seller to file its annual report with the FDA within thirty (30) days after Seller's request for such documentation.
Right to Reference. Partner shall, free of charge, license, transfer, provide a letter of reference with respect to, or take other action necessary to make available any INDs or NDAs related to Product as may be reasonably necessary to enable Nycomed or its designee to exercise its rights and fulfill its obligations pursuant to this Agreement.
Right to Reference. Each party has the right to publicly disclose the existence of the relationship between the parties as defined by this Agreement, general range of Mailboxes served by the Binary Software (i.e., references to “tens of thousands”, “millions”, etc., as the case may be) and other details that the parties agree to in writing in advance of disclosure. The parties agree to issue a press release announcing this relationship and its general scope at the ISPCON Spring 2007 Conference on May 23-25, 2007, provided that in the event the implementation of the NiM Platform and Webmail AJAX Beta 3 application as set out in subsection 1.3.1(ii) has not been completed prior to such date, such news release shall be issued thirty (30) days following the first Activated Mailbox.
